Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + TPF induction followed by cetuximab + radiotherapy in locally advanced resectable SCCHN
2007-002782-12Phase 4Completed
- Sponsor
- National Institute of Oncology
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Institute of Oncology. Primary endpoint: Complete response rate at week 25 among patients continuing cetuximab at week 6. Started Jul 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-002782-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002782-12.